What are the Challenges of Targeting VEGFR in Cancer?
While targeting VEGFR has shown promise, there are several challenges:
Resistance: Tumors can develop resistance to VEGFR inhibitors through various mechanisms, such as upregulation of alternative angiogenic pathways. Toxicity: Inhibiting VEGF/VEGFR can lead to side effects like hypertension, hemorrhage, and impaired wound healing. Heterogeneity: Tumors are often heterogeneous, and not all cells within a tumor may be equally dependent on VEGFR signaling.
